Utility of Experimental Design in Pre-Column Derivatization for the Analysis of Tobramycin by HPLC—Fluorescence Detection: Application to Ophthalmic Solution and Human Plasma

Asmaa A. El-Zaher and Marianne A. Mahrouse
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, Egypt.
Corresponding author email: mariannealphonse@yahoo.com

Abstract: A novel, selective, and sensitive reversed phase high-performance liquid chromatography (HPLC) method coupled with fluorescence detection has been developed for the determination of tobramycin (TOB) in pure form, in ophthalmic solution and in spiked human plasma. Since TOB lacks UV absorbing chromophores and native fluorescence, pre-column derivatization of TOB was carried out using fluorescamine reagent (0.01%, 1.5 mL) and borate buffer (pH 8.5, 2 mL). Experimental design was applied for optimization of the derivatization step. The resulting highly fluorescent stable derivative was chromatographed on C\textsubscript{18} column and eluted using methanol:water (60:40, v/v) at a flow rate of 1 mL min\textsuperscript{-1}. A fluorescence detector (\(\lambda_{\text{ex}}\) 390 and \(\lambda_{\text{em}}\) 480 nm) was used. The method was linear over the concentration range 20–200 ng mL\textsuperscript{-1}. The structure of the fluorescent product was proposed, the method was then validated and applied for the determination of TOB in human plasma. The results were statistically compared with the reference method, revealing no significant difference.

Keywords: tobramycin, experimental design, HPLC, derivatization, fluorescamine, plasma
Introduction

Tobramycin (TOB, Fig. 1) is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It exhibits a broad spectrum activity against aerobic gram-negative bacteria, particularly Pseudomonas aeruginosa, which makes it the antibiotic of choice in the treatment of pulmonary infections.\(^1,2\) The bactericidal activity of TOB is accomplished by inhibiting ribosomal function leading to interruption in bacterial protein synthesis.\(^3\) It is used topically for treatment of eye infections, parenterally for treatment of serious bacterial infection, and also for local application in the oral cavity and stomach as part of selective decontamination of the digestive tract.\(^1,4\) Like other aminoglycosides, the use of TOB can create potential dose-related side effects of ototoxicity and nephrotoxicity. Even though it is poorly absorbed, prolonged oral administration can produce such toxic effects.\(^3\) Therefore, careful monitoring of the drug level in plasma is required for therapeutic and toxic control, especially when therapy is of long duration.\(^5\)

Several analytical techniques were reported for the analysis of TOB in dosage forms and in biological fluids including spectrophotometry,\(^6-9\) spectrofluorimetry,\(^6,7,10\) capillary electrophoresis,\(^11\) and TLC densitometry.\(^12,13\) A number of high-performance liquid chromatography (HPLC) methods were described using specific detection modes such as evaporative light scattering detection,\(^14,15\) pulsed electrochemical detector, and tandem mass spectrometry.\(^16-18\) Chemically, TOB consists of amino sugars linked glycosidically with 1,3-diaminocyclohexane central ring.\(^19\) Like most carbohydrates, TOB lacks UV absorbing chromophores and does not possess native fluorescence, leading to a major challenge in the analysis of such a compound due to problematic detection.\(^20\) Therefore, derivatization with a suitable absorbance-enhancing or fluorescence-producing agent is required for the detection by chromatographic techniques. HPLC methods with fluorescence detection, after derivatization\(^21\) or indirect fluorescence detection, based on ligand displacement\(^22\) were previously employed. However, most of these techniques have various limitations, for example, the use of 2,4,6-trinitrobenzenesulfonic acid\(^23\) and 1-fluoro-2,4-dinitrobenzene\(^24\) as pre-column derivatizing agents is undesirable due to their high toxicity. The main disadvantages of 2,4-dinitrofluorobenzene reagent, employed by USP,\(^25\) and fluorescein isothiocyanate\(^21\) were the length of time and the temperature required to achieve the reaction. O-phthalaldehyde, used in post-column derivatization, led to the formation of a derivative with poor stability.\(^26\) Therefore, the objectives of this work were to employ a non toxic derivatizing agent and to enhance the formation of a more stable fluorescent derivative while maintaining high sensitivity.

Fluorescamine reagent is a useful derivatizing reagent that reacts with primary amino group to form fluorescent pyrrolonine moieties.\(^27\) Optimization of the pre-column derivatization step was performed using Design of Experiments (DOE) approach. The chemometric approach requires a relatively limited number of experiments to define the factors which affect the derivatization reaction and to obtain the optimum conditions for the formation of fluorescent derivative.\(^28,29\)

This manuscript describes the development of a new HPLC method coupled with fluorescence detection for the analysis of TOB after pre-column derivatization. The validated method was applied for the determination of TOB in eye drops and in spiked human plasma.

Experimental

Instrumentation

All fluorescence measurements were carried out using a Shimadzu RF—1501 Spectrofluorophotometer (Shimadzu Corporation, Kyoto, Japan),
with excitation and emission band pass of 5 nm using 1 cm quartz cell. Experimental matrices, three dimensional (3D) surface plots, and contour curves were generated using Minitab (Version 15) statistical software (State College, Pennsylvania, USA). The chromatographic system was composed of a solvent delivery (LC-10AD, Shimadzu, Japan), a system controller model CBM-20A Communications BUS module and a spectrofluorometric detector (RF-551) with excitation and emission wavelengths set at 390 nm and 480 nm, respectively. Separation was achieved on Waters C$_{18}$ column (250 × 4.6 mm, i.d.) packed with 5 μm particle size (USA). The mobile phase was composed of methanol:water (60:40, v/v) and pumped at 1 mL min$^{-1}$ flow rate. The mobile phase was filtered through 0.45 μm membrane filter (Sartorius Stedim Biotech GmbH, Germany) and degassed before use. All the work was carried out at room temperature, at Center of Applied Research and Advanced Study (CARAS) in Faculty of Pharmacy, Cairo University.

Materials and reagents

All chemicals and solvents were of analytical reagent grade. TOB sulfate pure sample was kindly supplied by Sigma Chemical Co., Germany. Its purity was found to be 99.92 ± 0.56 according to the reference spectrophotometric method.$^{30}$ Pharmaceutical dosage form containing TOB sulfate was purchased from the local market. Tobrin® sterile ophthalmic solution (Batch No. 1202155) was labeled to contain 0.3% TOB base and was manufactured by Egyptian Int. Pharmaceutical Industries CO. (E.I.P.CO.), 10th of Ramadan City, Egypt. Fluorescamine was purchased from Sigma-Aldrich Chemie GmbH, Germany and a stock solution of 0.01% w/v was prepared in acetone (Chromasolv, Sigma—Aldrich Chemie GmbH, Germany). The solution was stable for at least 7 days, if kept in the refrigerator. Aqueous borate buffer solution (pH 8.5) was prepared by mixing appropriate volumes of 0.2 M boric acid/0.2 M potassium chloride with 0.1 M sodium hydroxide and adjusting the pH to 8.5 using pH meter.$^{31}$ Boric acid, potassium chloride and sodium hydroxide (El-Nasr Pharmaceutical Chemicals, Egypt) were of analytical reagent grade. Drug free human plasma was obtained from blood transfusion center, Cairo University, Kasr El-Aini hospital (Cairo, Egypt) and stored at −20 °C until use after gentle thawing to room temperature.

Preparation of the standard solutions

Stock solution of TOB sulfate was prepared by dissolving 10 mg of the drug in 100 mL of distilled water. This solution was further diluted with the same solvent in order to obtain a working standard solution of a final concentration of 1 μg mL$^{-1}$ of TOB sulfate.

Experimental design for optimization of pre-column derivatization reaction

A three-level face centered composite (FCC) design with five center points was applied to evaluate main, interaction, and quadratic effects of the factors affecting the pre-column derivatization reaction. Buffer pH, volume of the buffer, and volume of fluorescamine reagent were investigated in three different levels of each. Table 1 shows the experimental planning proposed by DOE. A total of 20 experiments, including five central points, were conducted, each experiment corresponds to a particular combination of the different levels of factors. The corresponding fluorescence intensities were measured and the data were analyzed using Minitab (version 15) statistical software. The model obtained was described by the following general mathematical second-order equation:$^{32}$

$$Y = b_0 + b_1X_1 + b_2X_2 + b_3X_3 + b_{11}X_1^2 + b_{22}X_2^2 + b_{33}X_3^2 + b_{12}X_1X_2 + b_{13}X_1X_3 + b_{23}X_2X_3$$  \hspace{1cm} (1)

Where $Y$ is the response; $b_0$ is the arithmetic mean response; $b_1$, $b_2$ and $b_3$ are the regression coefficients of the factors $X_1$, $X_2$ and $X_3$, respectively; $b_{12}$, $b_{13}$ and $b_{23}$ are interaction terms; and $b_{11}$, $b_{22}$ and $b_{33}$ are square regression coefficients terms. The terms $b_1X_1$, $b_2X_2$, and $b_3X_3$ are the individual effects of each factor. $b_{12}X_1X_2$, $b_{13}X_1X_3$, and $b_{23}X_2X_3$ indicate the interaction among the factors, and the terms $b_{11}X_1^2$, $b_{22}X_2^2$ and $b_{33}X_3^2$ are the quadratic terms of each factor.

Construction of calibration graph

Aliquots of TOB sulfate working standard solution containing a final drug concentration of 20–200 ng mL$^{-1}$ were transferred into a series of 10 mL volumetric flasks. To each flask, 2 mL of borate buffer with pH 8.5 were added followed by 1.5 mL of FL reagent (0.01% w/v).
Each solution was shaken for 5 minutes and then filled to flask volume with distilled water. After standing for 15 minutes, 20 µL portions of each solution were injected in three replicates into the chromatograph. The eluents were detected by the fluorescence detector with the wavelength of excitation fixed at 390 nm and that of emission fixed at 480 nm. The signals emerging from the detector were integrated as peak area and a calibration graph was obtained by plotting the peaks areas against the corresponding concentrations of TOB sulfate and the regression equation was computed.

### Analysis of pharmaceutical dosage form

Sample solution of TOB was prepared at a concentration of 1.2 µg mL\(^{-1}\) by diluting 1 mL of Tobrin® eye drops (equivalent to 3 mg TOB base) to 25 mL with distilled water, then diluting 1 mL of the resulting solution to 100 mL with the same solvent. Different aliquots of the obtained solution were analyzed using the procedure mentioned in the section “Construction of calibration graph.”

### Procedure for spiked human plasma

Aliquots of drug free human plasma (1 mL) were transferred into a series of centrifuge tubes and spiked with different concentrations of TOB sulfate standard solution. Acetonitrile (2 mL) was then added to each tube to precipitate the plasma proteins. The samples were mixed by vertical agitation (2 minutes) using vortex apparatus and centrifuged at 3000 rpm for 5 minutes. The resulting supernatant was transferred into a clean glass tube and evaporated to dryness in a water bath (40 °C). The residue obtained was reconstituted in distilled water (1 mL) and the obtained solutions were analyzed using the procedure mentioned in section “Construction of calibration graph.” The area under the peak, arising at a retention time 3 ± 0.1 minutes, was recorded and the concentration of the drug in plasma was determined by using the regression equation.

### Determination of the stoichiometry of the reaction

Based on the optimum experimental conditions, the stoichiometry of the reaction was studied by adopting the limiting logarithmic method. Log of the molar concentration of fluorescamine was plotted versus log of the fluorescence intensity using constant concentration of TOB. Additionally, log of the molar concentration of TOB was plotted versus log of the fluorescence intensity using constant concentration

---

**Table 1. Experimental matrix and experimental plan of the face centered composite design.**

| Number of experiments | Experimental variables | Buffer pH | Volume of buffer (mL) | Volume of fluorescamine (mL) |
|-----------------------|------------------------|-----------|-----------------------|-------------------------------|
| 1                     | -1 -1 -1               | 7.5       | 1                     | 0.5                           |
| 2                     | 0 1 0                 | 8.5       | 3                     | 1.0                           |
| 3                     | 0 0 1                 | 8.5       | 2                     | 1.5                           |
| 4                     | 0 -1 0                | 8.5       | 1                     | 1.0                           |
| 5                     | 1 -1 -1               | 9.5       | 1                     | 0.5                           |
| 6                     | 0 0 0                 | 8.5       | 2                     | 1.0                           |
| 7                     | -1 1 1                | 7.5       | 3                     | 1.5                           |
| 8                     | 0 0 0                 | 8.5       | 2                     | 1.0                           |
| 9                     | 0 0 0                 | 8.5       | 2                     | 1.0                           |
| 10                    | 1 -1 1                | 9.5       | 1                     | 1.5                           |
| 11                    | -1 0 0                | 7.5       | 2                     | 1.0                           |
| 12                    | 1 1 1                | 9.5       | 3                     | 1.5                           |
| 13                    | -1 -1 1              | 7.5       | 1                     | 1.5                           |
| 14                    | 0 0 0                 | 8.5       | 2                     | 1.0                           |
| 15                    | -1 1 -1              | 7.5       | 3                     | 0.5                           |
| 16                    | 1 0 0                | 9.5       | 2                     | 1.0                           |
| 17                    | -1 0 0               | 8.5       | 2                     | 1.0                           |
| 18                    | 1 1 -1              | 9.5       | 3                     | 0.5                           |
| 19                    | 0 0 -1                | 8.5       | 2                     | 0.5                           |
| 20                    | 0 0 0                | 8.5       | 2                     | 1.0                           |
of fluorescamine. The slopes of the two straight lines obtained were measured.

**Results and Discussion**

TOB structure is characterized by the presence of saturated ring system that does not exhibit any significant absorption in the UV and visible region. The very low absorptivity of TOB does not permit its direct quantification at low concentrations, particularly if there is need to estimate the drug in plasma or in biological fluids. The problem could be solved by derivatizing the compound by a suitable fluorogenic reagent. Fluorescamine offers enhanced fluorescence detection of primary amine. It has no inherent fluorescent property and is quickly hydrolyzed in water. Additionally, degradation products are non-fluorescent. Therefore, the fluorescence of the solution containing amines and fluorescamine is proportional to the quantity of free amine groups present. Fluorescamine is widely used as a derivatizing reagent for the determination of many drugs, such as amoxicillin and oseltamivir. Since TOB contains primary aliphatic amino group, it reacted with fluorescamine in alkaline medium, at room temperature. The condensation reaction was complete in a few minutes and formed a highly fluorescent pyrrolinone derivative. The formed stable fluorescent derivative of TOB was quantified in ophthalmic solution and spiked human plasma using HPLC method coupled with fluorescence detection.

**Optimization of the pre-column derivatization reaction conditions**

The traditional method performed for optimization of reaction conditions was based on changing one variable at a time (OVAT approach) which did not depict the combined effects of all the variables involved in the reaction. Therefore, experimental design using FCC design was applied to facilitate method development by varying all the factors together. FCC design has distinct advantages, such as the use of minimum number of experiments and feasibility of generating data that can be analyzed statistically to provide valuable information on the interactions among experimental parameters.

Scanning of the excitation and emission spectra of the reaction product of fluorescamine with TOB showed that optimal excitation and emission wavelengths were 390 nm and 480 nm, respectively (Fig. 2). Distilled water was the solvent of choice for the drug as alcohols were found to react with fluorescamine to form additional products that could drastically reduce the reactivity of the reagent toward primary amines. Borate buffer was found to be suitable as it contains no primary amines. The factors selected for consideration were buffer pH ($X_1$), volume of borate buffer ($X_2$), and volume of fluorescamine reagent ($X_3$).

The FCC design was applied and twenty experiments were conducted using the levels described in Table 1. The coefficients of the second—order polynomial model were computed and the following equation was deduced:

\[
y = -4725.49 + 1112.3X_1 + 51.39X_2 + 539.12X_3 - 60.86X_1^2 + 1.28X_2^2 - 129.08X_3^2 - 13.19X_1X_2 - 19.67X_1X_3 + 37.51X_2X_3
\]

Where $Y$ is the fluorescence intensity; and $X_1$, $X_2$, and $X_3$ are buffer pH, volume of buffer and volume of fluorescamine reagent, respectively.

From the values obtained for the parameters in the FCC design (Table 2), it could be established that the fluorescence intensity is directly related to all the three factors. Two of the factors have significant influence on the response, buffer pH, and volume of fluorescamine reagent ($P < 0.05$) which significantly increases the fluorescence intensity when they are increased. However, the significant quadratic term ($X_1^2$, $P = 0.024$) indicates non-linear correlation between the factor and the response, as revealed in the interaction plots (Fig. 3). The individual effects of buffer pH and volume of fluorescamine are positive while their quadratic effects are negative, thus
indicating that the fluorescence intensity increases with increase of the factor up to a critical threshold after which a further increase results in a decrease in the response (level 0 of \( X_1 \) and level 1 of \( X_3 \) were chosen). In addition, the interaction between the three factors is not significant \((P \geq 0.05)\).37

Pareto charts (Fig. 4) reveal that the factors which were statistically significant \((P \leq 0.05)\) are buffer pH and volume of fluorescamine, confirming the results deduced from the polynomial equation (2).37

Graphical evaluation, residual and statistical analysis of FCC design
Three dimensional response surface plots and two dimensional contour plots, keeping one of the variables at the central point, are presented in Figure 5. From these plots, optimal conditions for the pre-column derivatization reaction were derived. The highest fluorescence intensity was obtained upon using 2 mL of borate buffer pH 8.5 and 1.5 mL of fluorescamine (0.01% w/v in acetone). Contour plots showed curvature, indicating the non-linear effects of these factors on fluorescence intensity.28

Close inspection of Figure 6A reveals that the residuals fall on a straight line, indicating that the errors are normally distributed. Histogram of the residuals is bell-shaped indicating the absence of skewness and outliers (Fig. 6B). The plots of residuals versus fits and versus order (Fig. 6C and D) show that no obvious pattern appeared. An almost equal scatter above and below the X-axis can be observed, implying the absence of non-constant variance and that the proposed model is adequate.29

ANOVA analysis of the model reveals that the model is significant, that is, at least one of the terms in the regression equation (linear and quadratic terms) makes a significant impact on the mean response (Table 3). A non significant lack of fit \((P = 0.067)\) indicates that the model fits the data well and can be used to predict the fluorescence intensity of TOB within the limits of the experiment.29

Finally, the reaction was complete after shaking for 15 minutes and the product remained stable for at least 3 hours.

Stoichiometry and mechanism of the reaction
By applying the liming logarithm method,33 two straight lines were obtained with slope values of 0.41 and 0.45 (Fig. 7A). By dividing the slopes of the two lines, a value of 1.09 was obtained. It was therefore

---

**Table 2.** Estimated regression coefficients and associated probability values \((P\text{-value})\) for fluorescence intensity.

| Term                                      | Coefficients | \( P \) |
|-------------------------------------------|--------------|---------|
| Constant                                  | -4725.49     | 0.000   |
| Buffer pH                                 | 1112.30      | 0.025   |
| Volume of buffer                          | 51.39        | 0.162   |
| Volume of fluorescamine                   | 539.12       | 0.000   |
| Buffer pH * Buffer pH                     | -60.86       | 0.024   |
| Volume of buffer * volume of buffer       | 1.28         | 0.957   |
| Volume of fluorescamine * volume of buffer| -129.08      | 0.188   |
| Buffer pH * volume of buffer              | -13.19       | 0.348   |
| Buffer pH * volume of fluorescamine       | -19.67       | 0.479   |
| Volume of Buffer * volume of fluorescamine| 37.51        | 0.192   |
Figure 5. Response surface plots (A) and contour plots (B) showing the influence of studied factors on fluorescence intensity.

Figure 6. Residual plots for fluorescence intensity: Normal probability plot (A), histogram (B), residuals versus fits (C), and residuals versus order (D).
concluded that the reaction proceeds in a molar ratio of 1:1. This could be attributed to the decreased basicity of the amino group by its vicinal hydroxyl groups, leaving only one amino group (NH$_2$*) with enough basicity to react with fluorescamine.$^{38}$

Based upon these facts and the previous reported studies,$^{27}$ the reaction pathway between TOB and fluorescamine could be represented as shown in Figure 7B.

### Development of the chromatographic method

A variety of mobile phases were investigated in the development of the HPLC-fluorescence detection method for the analysis of TOB. The suitability of mobile phase was decided on the basis of assay sensitivity, suitable retention time, and peak shape. A mobile phase consisting of methanol:water in different ratios was first tried. It was found that increasing the volume of water helped to sharpen the peak of TOB. Replacing methanol with acetonitrile distorted the peak shape with no significant change in retention time. A mobile phase composed of methanol:water (60:40, v/v) at a flow rate of 1 mL min$^{-1}$ gave sharp peak of TOB at a retention time of 3 ± 0.1 minutes (Fig. 8A).

Upon optimization of the factors affecting the fluorescence intensity in the pre-column derivatiza-

---

**Table 3. Analysis of variance (ANOVA) results for fluorescence intensity.**

| Source          | $P$  |
|-----------------|------|
| Regression      | 0.000|
| Linear          | 0.000|
| Square          | 0.005|
| Interaction     | 0.374|
| Residual error  |      |
| Lack-of-fit     | 0.067|

---

**Figure 7.** (A) Stoichiometry of the reaction between TOB sulfate and fluorescamine reagent by adopting the limiting logarithmic method, variable fluorescamine concentrations and constant TOB concentration ($A_1$), variable TOB concentrations and constant fluorescamine concentration ($A_2$). (B) Suggested pathway for the reaction between TOB and fluorescamine reagent.

**Figure 8.** HPLC chromatograms of: TOB sulfate standard solution (120 ng mL$^{-1}$) after pre-column derivatization with fluorescamine reagent (A), plasma spiked with 70 ng mL$^{-1}$ of TOB sulfate after derivatization with fluorescamine reagent (B) and Tobrin® eye drops (equivalent to 30 ng mL$^{-1}$ TOB base) (C).
Analysis of tobramycin by HPLC-fluorescence detection

**Linearity and range**

Linearity was evaluated by linear regression analysis. A linear relationship between the peak areas and the corresponding concentrations was demonstrated by a good correlation coefficient obtained for the regression line (0.9990), across the concentration range 20–200 ng mL\(^{-1}\). Data from the regression line was used to provide mathematical estimation of the degree of linearity. Parameters for the analytical performance of the proposed method and descriptive statistics of the regression line were revealed in Table 4.

**Accuracy**

Accuracy of the suggested method was evaluated by replicate analysis and recovery determination of pure samples of TOB covering the linearity range (Table 5). The results obtained were compared with those obtained using the reference spectrophotometric method.\(^{30}\) Statistical analysis, using student’s \(t\)-test and variance ratio \(F\)-test, revealed no significant difference between the proposed method and the reported one with respect to accuracy and precision (Table 6).

Furthermore, the validity of the suggested method was evaluated by applying the standard addition technique. Recovery results suggest that the method was unaffected by the presence of formulation excipients and confirm high accuracy (Table 7).

**Precision**

Table 4 summarizes the results of the determination of intraday and interday assay precision. The intra-day assay precision of the method, based on within

### Table 4. Assay parameters and method validation obtained by applying HPLC-fluorescence detection method for the determination of TOB.

| Parameter                        | TOB             |
|----------------------------------|-----------------|
| Excitation wavelength            | 390 nm          |
| Emission wavelength              | 480 nm          |
| Retention time (min)             | 3 ± 0.1         |
| Tailing factor                   | 0.9             |
| Number of theoretical plates     | 2130.462        |
| Height equivalent to theoretical plate (HETP)| 0.0117         |
| Range of linearity               | 20–200 ng mL\(^{-1}\) |
| Regression equation              | \( y = 0.0243 x + 1.0652 \) |
| Correlation coefficient \((r)\)  | 0.9990          |
| \(S_a\)                          | 0.001           |
| \(S_b\)                          | 0.061           |
| Confidence limit of the slope    | 0.0243 ± 0.003  |
| Confidence limit of the intercept| 1.0652 ± 0.194  |
| Standard error of the estimation | 0.069           |
| LOD\(^a\)                        | 5.34 ng mL\(^{-1}\) |
| LOQ\(^a\)                        | 16.30 ng mL\(^{-1}\) |
| Intraday\(^b\) % RSD             | 0.800–0.773–0.576 |
| Interday\(^c\) % RSD             | 0.789–0.773–0.331 |

Notes: \(^a\)Limits of detection and quantification are determined via calculations:\(^{39}\) LOD = 3.3 × SD/slope, LOQ = 10 × SD/slope, where SD is standard deviation of response; \(^b\)the intraday \((n = 3)\), average of three concentrations of TOB (40, 100, 180 ng mL\(^{-1}\)), repeated three times within the day; \(^c\)the interday \((n = 3)\), average of three concentrations of TOB (40, 100, 180 ng mL\(^{-1}\)), repeated three times in three successive days.

### Table 5. Application of the proposed HPLC-fluorescence detection method for the determination of TOB in pure samples and in spiked human plasma.

| Claimed taken (ng mL\(^{-1}\)) | Pure samples |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|---------------------------------|--------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|                                 | Claimed found (ng mL\(^{-1}\)) | % recovery\(^a\) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 40                              | 39.868        | 99.67          |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 100                             | 100.486       | 100.49         |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 140                             | 141.391       | 100.99         |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 170                             | 168.840       | 99.32          |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mean                            | 100.12        | 99.73          |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ± SD                            | 0.761         | 1.554          |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Note: \(^a\)Average of three determinations.

Method validation

The optimized chromatographic method was validated according to the International Conference on Harmonization (ICH) Q2 (R1) guidelines.\(^{39}\)
Table 6. Statistical analysis of the results obtained by applying the proposed HPLC-fluorescence detection method and the reference method.

| Item                  | HPLC-fluorescence detection method | Reference method |
|-----------------------|-----------------------------------|------------------|
| Pure form             | Mean                 | 100.12           | 99.92           |
|                       | SD                   | 0.761            | 0.56            |
|                       | n                    | 4                | 4               |
|                       | Variance             | 0.579            | 0.314           |
|                       | t-value              | 0.423 (2.447)*   |                 |
|                       | F-value              | 1.847 (9.28)*    |                 |

Note: *Figures in parentheses are the corresponding theoretical t- and F-values at P = 0.05.

The day repeatability, was performed by replicate analysis (n = 3) of three different concentrations of TOB standard solution covering three levels (low, medium and high) on the same day. The interday assay precision (intermediate precision) of the method was established by triplicate determination of the same three concentrations over a period of three successive days. The measured concentrations had relative standard deviation (RSD) values less than 2, indicating that the suggested method was precise.

Specificity
The method was developed to demonstrate the discrimination of the analyte in the presence of excipients in a pharmaceutical product and in human plasma. Specificity was indicated by the absence of any interference at the retention time of the peak of interest as evaluated by comparing the chromatograms of TOB pure sample, tobrin® eye drops, and plasma spiked with TOB. Figure 8 indicates that the suggested method was highly specific for the analysis of TOB.

Limit of detection and limit of quantification
According to ICH Q2B, the limit of detection (LOD) and limit of quantification (LOQ) were determined by establishing the minimum level at which the analyte can be reliably detected and the lowest concentration that can be measured, respectively. LOD and LOQ were calculated as 3.3 × SD/slope and 10 × SD/slope, respectively, where SD is the standard deviation of the response (Table 4).

System suitability
The system suitability test was performed according to the USP22 in order to check parameters such as tailing factor, number of theoretical plates and height equivalent to theoretical plate (HETP) (Table 4).

Analysis of TOB in spiked human plasma
The high sensitivity of the proposed method allowed the determination of TOB in human plasma. To avoid loss of analyte due to clean-up procedures and increase its recovery, the number of clean-up steps in a sample preparation procedure should be kept to a minimum. Protein precipitation is commonly used for fast sample clean-up and disrupting protein—drug binding. In the present method, acetonitrile was chosen as the protein precipitant as it resulted in good signal intensities, high extraction recoveries for TOB, and relatively clean chromatograms under fluorescence detection20 (Fig. 8b). Satisfactory results were obtained (Table 5).

Table 7. Application of the proposed HPLC-fluorescence detection method for the determination of TOB in pharmaceutical dosage form with application of standard addition technique.

| Pharmaceutical dosage form | Claimed (ng mL⁻¹) | % recovery a | Pure TOB added (ng mL⁻¹) | % recovery a |
|-----------------------------|--------------------|--------------|--------------------------|--------------|
| Tobrin® eye drops           | 60                 | 101.48       | 50                       | 98.93        |
|                             | 120                | 98.89        | 60                       | 99.11        |
|                             |                    |              | 70                       | 100.53       |
|                             | 180                | 100.95       | 50                       | 99.45        |
| Mean                        |                    | 100.44       | 60                       | 99.53        |
| ± SD                        |                    | 1.368        | 70                       | 101.13       |
|                             |                    |              |                          |              |
| Notes: aClaimed taken equivalent to TOB base; baverage of three different determinations.
Conclusion
A sensitive, precise, and accurate method based on HPLC coupled with fluorescence detection has been developed for the analysis of TOB in pure sample, eye drops, and spiked human plasma. Experimental design was successfully applied for optimization of the pre-column derivatization reaction, saving time, and cost. The method was successfully validated for linearity, accuracy, precision, and specificity. It offers several advantages including the use of non-toxic derivatizing reagent and high sensitivity. In addition, specificity was evident from the analysis of TOB in pharmaceutical dosage form and in spiked human plasma with no interference from excipients. The extraction procedure, using deproteinization of plasma samples, was simple and the recovery was more than 95%. Therefore, the proposed method was found to be suitable for routine analysis of the drug in quality control laboratories.

Author Contributions
Conceived and designed the experiments: AAZ and MAM. Analysed the data: AAZ and MAM. Wrote the first draft of the manuscript: MAM. Contributed to the writing of the manuscript: AAZ. Agree with manuscript results and conclusions: AAZ and MAM. Jointly developed the structure and arguments for the paper: AAZ and MAM. Made critical revisions and approved final version: AAZ and MAM. All authors reviewed and approved of the final manuscript.

Funding
This work was financially supported by the research committee in Faculty of Pharmacy, Cairo University.

Competing Interests
Authors disclose no potential conflicts of interest.

Disclosures and Ethics
As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.

References
1. Sweetman SC. Martindale, The Complete Drug Reference, 36th ed. London, Chicago: The Pharmaceutical Press; 2009:354.
2. Kalant H, Grant DM, Mitchell J. Principles of Medical Pharmacology, 7th ed. Elsevier Canada, a division of Reed Elsevier Canada, Ltd.; 2007:699–702.
3. Kumar P, Clark M. Clinical Medicine A Textbook for Medical Students and Doctors, 6th ed. Toronto, Tokyo: W.B. Saunders, Harcourt Brace and Company Limited; 2005:14.
4. Attema-de Jonge MF, Beksers JM, Oudemans-van Straaten HM, Sarrisana RW, Franssen EJF. Simple and sensitive method for quantification of low tobramycin concentrations in human plasma using HPLC-MS/MS. J Chromatogr B Analyt Technol Biom Life Sci. 2008;862(1–2):257–62.
5. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology, 7th ed. Churchill livingstone, Elsevier; 2012:670–1.
6. Abdel Ghany MF, El Kosasy AM, Ayad MF, Abdel Fattah LE. Spectrophotometric and spectrophluorimetric determination of gentamicin and tobramycin using 1,4-benzoquinone. Bull Fac Pharm Cairo Univ; 2003;41(1):69–88.
7. El Kosasy AM, Abdel Ghany MF, Ayad MF, Abdel Fattah LE. Colorimetric and spectrophotometric determination of gentamicin and tobramycin in pure, dosage forms and in mixture with dexamethazone. Bull Fac Pharm Cairo Univ. 2003;41(1):89–108.
8. Li W, Wu F, Zhang S. Determination of tobramycin eye drops by acid dye colorimetry. Yaoxue Jinzhan. 2011;35(3):133–5.
9. Shantier SW, Gadkariem EA, Hagg HS. Kinetic determination of tobramycin in drug formulations. Res J Pharm Biol Chem Sci. 2012;3(1):566–73.
10. El-Shabrawy Y. Fluorometric determination of aminoglycoside antibiotics in pharmaceutical preparations and biological fluids. Spectrosc Lett. 2002;35(1):99–109.
11. El-Attug MN, Hoogmartens J, Adams E, Van Schedepal A. Optimization of capillary electrophoresis method with contactless conductivity detection for the analysis of tobramycin. J Pharm Biomed Anal. 2012;58:49–57.
12. El Kosasy AM, Abdel Ghany MF, Ayad MF, Abdel Fattah LE. TLC and scanning densitometric method for determination of gentamicin and tobramycin in pure, dosage forms and in mixture with dexamethazone. Bull Fac Pharm Cairo Univ. 2003;41(2):169–77.
13. Hubicka U, Krzek J, Wolynska H, Stachacz B. Simultaneous identification and quantitative determination of selected aminoglycoside antibiotics by thin-layer chromatography and densitometry. J AOAC Int. 2009;92(4):1068–75.
14. Megouas NC, Kouparris MA. Development and validation of a novel HPLC/ELSD method for the direct determination of tobramycin in pharmaceuticals, plasma and urine. Anal Bioanal Chem. 2005;382(2):290–6.
15. Clarot I, Storme-Paris I, Chaminade P, Estevenon O, Nicolas A, Rieutord A. Simultaneous quantitation of tobramycin and colistin sulphate by HPLC with evaporative light scattering detection. J Pharm Biomed Anal. 2009;50(1):64–7.
16. Hanko VP, Rohrer JS. Determination of tobramycin and imipenem using high-performance anion exchange chromatography with integrated pulsed amperometric detection. J Pharm Biomed Anal. 2006;40(4):1006–12.
17. Keevil BG, Lockhart SJ, Cooper DP. Determination of tobramycin in serum using liquid chromatography–tandem mass spectrometry and comparison with a fluorescence polarization assay. J Chromatogr B Analyt Technol Biom Life Sci. 2003;794(2):329–35.
18. Cheng C, Liu S, Xiao D, Hansel S. The application of trichloroacetic acid as an ion-pairing reagent in LC-MS-MS method development for highly polar aminoglycoside compounds. Chromatographia. 2010;72(1–2):133–9.
19. Block JH, Beale JM. *Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry*, 11th ed. Philadelphia: Lippincott Williams & Wilkins, A Wolters Kluwer Company; 2004:345.

20. Dash AK. *Analytical Profiles of Drug Substances and Excipients*, 24, London, Toronto; Academic Press, Inc.; 1996:579–613.

21. Mashat M, Chrystyn H, Clark BJ, Assi KH. Development and validation of HPLC method for the determination of tobramycin in urine samples post-inhalation using pre-column derivatisation with fluorescein isothiocyanate. *J Chromatogr B Analyt Technol Biom Life Sci*. 2008;869(1–2):59–66.

22. Yang M, Tomellini SA. Non-derivatization approach to high-performance liquid chromatography-fluorescence detection for aminoglycoside antibiotics based on a ligand displacement reaction. *J Chromatogr A*. 2001;939(1–2):59–67.

23. Dash AK, Suryanarayanan R. A liquid-chromatographic method for the determination of tobramycin. *J Pharm Biomed Ana*. 1991;9(3):237–45.

24. Barends DM, Brouwers JCAM, Hulschoof A. Fast pre-column derivatization of aminoglycosides with 1-fluoro-2,4-dinitrobenzene and its application to pharmaceutical analysis. *J Pharm Biomed Anal*. 1987;5(6):613–7.

25. The United States Pharmacopeia (USP 30). The National Formulary (NF 25), Asian Ed.; 2007:3367–74.

26. Lai F, Sheehan T. Enhancement of detection sensitivity and cleanup selectivity for tobramycin through pre-column derivatization. *J Chromatogr*. 1992;609(1–2):173–9.

27. Walash MI, Belal F, El-Enany N, El-Maghrabey MH. Simple and sensitive spectrofluorimetric method for the determination of pregabalin in capsules through derivatization with fluorescamine. *Luminescence*. 2011;26(5):342–8.

28. Miller JN, Miller JC. *Statistics and Chemometrics for Analytical Chemistry*, 6th ed. England: Pearson education Limited; 2010:186–216.

29. Khamanga SM, Walker RB. The use of experimental design in the development of an HPLC-ECD method for the analysis of captopril. *Talanta*. 2011;83(3):1037–49.

30. Sampath S, Robinson DH. Comparison of new and existing spectrophotometric methods for the analysis of tobramycin and other aminoglycosides. *J Pharm Sci*. 1990;79(5):428–31.

31. Toro G, Ackermann PG. *Practical Clinical Chemistry*, 1st ed. Boston, Little, Brown and Company; 1975:740.

32. Deming SN, Morgan SL. *Experimental Design: A Chemometric Approach*, 2nd ed. Amsterdam, London, New York: Tokyo Elsevier Publishers; 1991: 151–69, 227–74.

33. Rose J. *Advanced Physicochemical Experiments*. London, Pitman; 1964:67.

34. Mascher HJ, Kikuta C. Determination of amoxicillin in human serum and plasma by high-performance liquid chromatography and on-line postcolumn derivatisation. *J Chromatogr A*. 1998;812(1–2):221–6.

35. Aydogmas Z. Simple and sensitive spectrofluorimetric method for the determination of oseltamivir phosphate in capsules through derivatization with fluorescamine. *J fluoresce*. 2009;19(4):673–9.

36. Udenfriend S, Stein S, Böhlen P, Dairman W, Leimgruber W, Weigele M. *Fluorescamine: A Reagent for Assay of Amino Acids, Peptides, Proteins, and Primary Amines in the Picomole Range*, Science. 1972;178:871–2.

37. Awotwe-Otoo D, Agarabi C, Faustino PJ, et al. Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate. *J Pharm Biomed Anal*. 2012;62:61–7.

38. Wang H, Tor Y. Electrostatic interactions in RNA aminoglycosides binding. *J Am Chem Soc*. 1997;119:8734–5.

39. Q2 (R1) Validation of analytical procedures, Proceedings of the International Conference on Harmonisation (ICH), Geneva. Commission of the European Communities (1996).

40. Muchohi SN, Thuo N, Karisa J, Muturi A, Kokwaro GO, Maitland K. Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. *J Chromatogr B*. 2011;879(2):146–52.